WO2021210804A1 - Procédé de préparation de cellulose microfibrillée d'algue rouge, et son utilisation - Google Patents

Procédé de préparation de cellulose microfibrillée d'algue rouge, et son utilisation Download PDF

Info

Publication number
WO2021210804A1
WO2021210804A1 PCT/KR2021/003752 KR2021003752W WO2021210804A1 WO 2021210804 A1 WO2021210804 A1 WO 2021210804A1 KR 2021003752 W KR2021003752 W KR 2021003752W WO 2021210804 A1 WO2021210804 A1 WO 2021210804A1
Authority
WO
WIPO (PCT)
Prior art keywords
red algae
cellulose
preventing
microfibrillated cellulose
skin damage
Prior art date
Application number
PCT/KR2021/003752
Other languages
English (en)
Korean (ko)
Inventor
정영훈
정성근
소보람
장정화
Original Assignee
경북대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020210037118A external-priority patent/KR102587264B1/ko
Application filed by 경북대학교 산학협력단 filed Critical 경북대학교 산학협력단
Publication of WO2021210804A1 publication Critical patent/WO2021210804A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9706—Algae
    • A61K8/9717—Rhodophycota or Rhodophyta [red algae], e.g. Porphyra
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B1/00—Preparatory treatment of cellulose for making derivatives thereof, e.g. pre-treatment, pre-soaking, activation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N5/00—Analysing materials by weighing, e.g. weighing small particles separated from a gas or liquid
    • G01N5/04—Analysing materials by weighing, e.g. weighing small particles separated from a gas or liquid by removing a component, e.g. by evaporation, and weighing the remainder

Definitions

  • the present invention relates to a method for manufacturing red algae microfibrillated cellulose (MFC) and its use, and more particularly, to a method for manufacturing red algae microfibrillated cellulose (MFC) and a composition for improving skin cell damage thereof will be.
  • MFC red algae microfibrillated cellulose
  • Skin aging can be divided into intrinsic aging and extrinsic aging according to factors. It is known that intrinsic aging is caused by changes in the physiological functions of the skin epidermis and dermis according to age, and extrinsic aging is caused by changes in the physiological functions of the skin caused by environments such as air pollution, UV exposure, and stress. Among these mechanisms of aging, oxidative stress induced by UV increases free radicals in the body, increases the activity of MMP-1 that decomposes collagen, and reduces hyaluronic acid. Degradation causes damage to the epidermis and dermis of the skin due to increased activity of hyaluronidase.
  • Red algae are composed of agar and cellulose, and form tetraspores, monospores, and bispores by asexual reproduction. It is divided into an annular shape, a cross shape, or a triangular pyramid shape. Sexual reproduction is accomplished by single-phase gametophytes, which form sperm and oviparous phases, respectively, and the carpospores produced as a result of their fertilization. Because it represents the morphology, it is regarded as one of the main distinguishing traits of the taxa. Therefore, the life history of red algae is based on the so-called Polysiphonia-type generational alternation, in which three generations of carposporophytes are alternately repeated by the union of spores, gametes, and gametes.
  • Red algae are largely divided into the protozoan subclass (Bangiophycidae; Protoflorideophycidae), to which seaweed and purple hair, and the like, and Florideophycidae, to which the algae, and the red algae belong.
  • the former includes Goniotrichales and Bangiales , the latter include Nemaliales, Gelidiales, Cryptonemiales, Gigartinales, Rhodymeniales, and Ceramiales.
  • seaweed has a softer tissue, finer fibers, and can be cultured in a much larger space than on land without special management, so it has a lot of biomass.
  • the growth rate is also faster than that of trees, does not require a separate soil for cultivation, and the pulping process is simple due to the easy extraction of fibers, and the production facilities are inexpensive.
  • studies are underway to use this seaweed pulp to improve skin hydration and adsorb harmful substances.
  • the method for producing red algae fibrillar cellulose of the present invention and its use for inhibiting skin damage or inflammation.
  • MFC red algae microfibrillated cellulose
  • Another object of the present invention is to provide a pharmaceutical composition for preventing or treating skin damage comprising red algae microfibrillated cellulose prepared by the above method.
  • Another object of the present invention is to provide a cosmetic composition for preventing or improving skin damage comprising red algae microfibrillated cellulose prepared by the above method.
  • Another object of the present invention is to provide a health food and health functional food composition for preventing or improving skin damage comprising red algae microfibrillated cellulose prepared by the above method.
  • Another object of the present invention is to provide a pharmaceutical composition for preventing or treating inflammatory diseases comprising the red algae microfibrillated cellulose prepared by the above method.
  • Another object of the present invention is to provide a method for confirming fibrillation of red algae cellulose.
  • Another object of the present invention is to provide a method for preventing or treating skin damage or inflammatory disease comprising administering the pharmaceutical composition to an individual.
  • Another object of the present invention is to provide a method for improving skin damage or alleviating inflammation, comprising the step of topically applying the cosmetic composition to an individual in an effective amount.
  • the present invention is a step of pre-treating red algae with a microwave sample decomposing device (microwave) to remove agar and physically blending the pre-treated red algae (red algae). It provides a method for producing red algae microfibrillated cellulose comprising the step.
  • microwave microwave sample decomposing device
  • the present invention provides a pharmaceutical composition for preventing or treating skin damage comprising red algae microfibrillated cellulose prepared by the above method.
  • the present invention provides a cosmetic composition for preventing or improving skin damage comprising red algae microfibrillated cellulose prepared by the above method.
  • the present invention provides a health food and health functional food composition for preventing or improving skin damage comprising red algae microfibrillated cellulose prepared by the above method.
  • the present invention provides a pharmaceutical composition for preventing or treating inflammatory diseases comprising red algae microfibrillated cellulose prepared by the above method.
  • the present invention provides a method for confirming fibrillation of red algae cellulose, comprising the step of determining whether the fibers of the cellulose are fibrillated.
  • the present invention provides a method for preventing or treating skin damage or inflammatory disease comprising administering the pharmaceutical composition to an individual.
  • the present invention provides a method for improving skin damage or alleviating inflammation comprising the step of topically applying the cosmetic composition to an individual in an effective amount.
  • Red algae microfibrillated cellulose according to the manufacturing method of the present invention is excellent in cyclooxygenase-2 (cyclooxygenase-2, Cox-2) activity inhibitory effect, MAPKs phosphorylation inhibitory effect, TNF- ⁇ expression inhibitory effect It has the effect of suppressing skin damage and inflammation caused by UV rays.
  • 1 is a diagram showing the contents of glucan and galactan after microwave pretreatment of red algae agar agar.
  • FIG. 2 is a view showing the structural change according to the microwave pretreatment temperature of the red algae agar agar.
  • Figure 3 is a diagram showing the water retention (water retention value) according to the physical treatment (blending) time of red algae cellulose.
  • Figure 4 is a diagram showing the results of the precipitation test according to the physical treatment (blending) time of red algae cellulose.
  • Figure 5 is a diagram showing the binding force of cellulose and Carbohydrate binding module protein according to the physical treatment (blending) time of red algae cellulose.
  • FIG. 6 is a view of observing the fibers of red algae cellulose that vary depending on the presence or absence of physical treatment (blending).
  • FIG. 7 is a diagram showing the COX-2 inhibitory activity of red algae microfibrillated cellulose.
  • FIG. 8 is a diagram showing the MAPK phosphorylation inhibitory activity of red algae microfibrillated cellulose.
  • FIG. 9 is a diagram showing the TNF- ⁇ expression inhibitory activity of red algae microfibrillated cellulose.
  • the present invention includes a first step of removing agar by pre-treating red algae by microwave decomposition, and a second step of blending red algae from which the agar is removed. It provides a method for producing red algae microfibrous cellulose (microfibrillated cellulose).
  • the red algae microfibrillated cellulose manufacturing method is a solvent such that the content of red algae is 5 to 15% (w/v), preferably 8 to 12% (w/v).
  • step 1-2 when the agar is not sufficiently removed when the pretreatment is performed at a temperature of 110 ° C. or lower, and when the pretreatment is performed at a temperature of 190 ° C. or higher, decomposition of glucan and by-products are generated, so the mixture is determined in the present invention It is preferable to pre-treat under true conditions, but is not limited thereto.
  • the cellulose is blended at 32000 to 42000 RPM, preferably 35000 to 39000 RPM for 40 minutes or more, preferably 80 minutes or more, more preferably 150 to 170 minutes. It may be to fibrillation.
  • red algae used in the present invention refers to seaweed that has red or purple color because it contains red algae and blue algae in addition to chlorophyll, and includes all seaweeds classified as red algae taxonomically.
  • seaweed Porphyra tenera
  • agaric agar Galidium amansii
  • grasshopper Gloiopeltis tenax
  • sagebrush Gramcilaria verrucosa
  • chaff Choondrus ocellatus Holmes
  • gambling Pachymeniopsis elliptica
  • silkworm Grateloupia filicina
  • Ceramium kondoi may include any one or more species from the group consisting of Hypnea charoides, preferably a seaweed of the family Gelidiaceae, more preferably a seaweed of the genus Gelidium, most preferably may be agar agar (Gelidium amansii).
  • the red algae are composed of agar and cellulose, and the agar is D-galactose and 3,6-anhydro-alpha-L- It may be composed of lactose (3,6-anhydro- ⁇ -L-lactose).
  • the manufacturing method may further include the step of determining whether agar is removed by measuring the galactan content.
  • galactan refers to a polysaccharide having a D-galactose residue as a constituent sugar. In the present invention, it was used to confirm the D-galactose content of red algae.
  • microwave decomposition method used in the present invention is one of the pretreatment methods for removing organic substances and interfering substances in the sample by adding distilled water to the sample and heating it.
  • the sample is heated using the principle that the temperature rises by causing (dipole moment) and ionic conductance.
  • red algae nanocellulose is prepared by removing agar from red algae and extracting cellulose using a microwave decomposition method.
  • the blending means physical treatment, from the form of a fine thread or ribbon to a fiber having a long and intact fibrous structure of cellulose (see FIG. 6A) through homogenization of a sample to a fiber such as a broad sheet It may mean to deform into fibers of various sizes (see FIG. 6B ) to make the fibers fibrillated.
  • the present invention provides a pharmaceutical composition for the prevention or treatment of skin damage or inflammatory diseases comprising red algae microfibrillated cellulose prepared by the above method.
  • the skin damage may be caused by ultraviolet rays, but is not limited thereto.
  • the term “damage” as used in the present invention includes apoptosis of human skin cells by ultraviolet rays, DNA damage of skin cells, an increase in reactive oxygen species (ROS), an increase in lipid peroxidation, and the like, and the symptoms include erythema, It may include sunburn, pigmentation, photoaging, skin cancer, and the like.
  • “improvement” of damage refers to any action of alleviating the damage state of the skin cells by the ultraviolet rays or reducing the degree of symptoms.
  • the inflammatory disease is arthritis, gout, hepatitis, asthma, obesity, keratitis, gastritis, enteritis, nephritis, diabetes, tuberculosis, bronchitis, pleurisy, peritonitis, spondylitis, pancreatitis, inflammatory pain, urethritis, cystitis, arteriosclerosis, sepsis, It may be selected from the group consisting of burns, dermatitis, periodontitis and gingivitis, but is not limited thereto.
  • red algae fibrillar cellulose may inhibit cyclooxygenase-2 (Cox-2) activity.
  • cyclooxygenase-2 (Cox-2) is also called prostaglandin-endoperoxide synthase 2, and prostaglandin, a substance that causes inflammation and pain.
  • prostaglandin, PGs means an enzyme that promotes the formation.
  • the prostaglandins are known to be deeply involved in cancer development, such as promoting inflammatory responses such as pain and fever, immune responses, and angiogenesis. have.
  • red algae fibrillar cellulose may inhibit the phosphorylation level of JNK and p38 mitogen-activated protein kinase (MAPK).
  • MAPK mitogen-activated protein kinase
  • red algae fibrillar cellulose may inhibit the expression of TNF- ⁇ .
  • the pharmaceutical composition for preventing or treating skin damage is an external preparation for skin having an effect of protecting the skin from ultraviolet rays, such as cream, gel, patch, spray, ointment, warning agent, lotion, liniment agent, pasta agent or cataplasma agent. It can be prepared and used as a pharmaceutical composition in the form of an external preparation for skin, but is not limited thereto.
  • prevention means any action that reduces the frequency or degree of occurrence of a pathological phenomenon. Prevention may be complete or partial. In this case, it may mean a phenomenon in which the symptoms of skin disease or inflammatory disease in the individual are reduced compared to the case where the composition is not used.
  • treatment refers to any action that clinically intervenes to alter the natural process of a subject or cell to be treated, and may be performed while a clinical pathology is in progress or to prevent it.
  • the desired therapeutic effect is to prevent the occurrence or recurrence of a disease, alleviate symptoms, decrease all direct or indirect pathological consequences of the disease, prevent metastasis, reduce the rate of disease progression, or reduce the disease progression rate. alleviating or temporarily ameliorating the condition, or improving the prognosis.
  • composition according to the present invention may contain a pharmaceutically effective amount of red algae fibrillar cellulose alone or may contain one or more pharmaceutically acceptable carriers, excipients or diluents.
  • pharmaceutically effective amount refers to an amount sufficient to prevent, improve and treat symptoms of immune diseases.
  • pharmaceutically acceptable refers to a composition that is physiologically acceptable and does not normally cause allergic reactions such as gastrointestinal disorders, dizziness, or similar reactions when administered to humans.
  • composition comprising a pharmaceutically acceptable carrier may be in various oral or parenteral formulations.
  • a diluent or excipient such as a filler, extender, binder, wetting agent, disintegrant, surfactant, etc. commonly used.
  • the carriers, excipients and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, Polyvinyl pyrrolidone, physiological saline, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, dextrin, calcium carbonate, may be at least one selected from the group consisting of propylene glycol and liquid paraffin, but It is not limited, and all conventional carriers, excipients or diluents may be used.
  • the ingredients may be added independently or in combination to the active ingredient, red algae fibrillar cellulose.
  • solid preparations for oral administration may include tablet pills, powders, granules, capsules, etc., and these solid preparations include one or more compounds and at least one excipient, for example, starch, calcium carbonate, sucrose. Alternatively, it may be prepared by mixing lactose, gelatin, and the like. In addition to simple excipients, lubricants such as magnesium stearate, talc and the like may also be used.
  • Liquid formulations for oral administration include suspensions, internal solutions, emulsions, syrups, etc. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. have.
  • Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspension solutions, emulsions, lyophilized formulations, suppositories, and the like.
  • Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate.
  • injectable esters such as ethyl oleate.
  • As the base of the suppository witepsol, macrogol, tween 61, cacao butter, laurin, glycerol, gelatin, etc. may be used.
  • the pharmaceutical composition of the present invention is a group consisting of tablets, pills, powders, granules, capsules, suspensions, internal solutions, emulsions, syrups, sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations and suppositories It may have any one formulation selected from As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin, glycerol, gelatin, etc. may be used.
  • the effective dose of the red algae fibrillar cellulose of the present invention to the human body may vary depending on the patient's age, weight, sex, dosage form, health status and disease level, and is generally about 0.001-100 mg/kg/day. and preferably 0.01-35 mg/kg/day. Based on an adult patient weighing 70 kg, it is generally 0.07-7000 mg/day, preferably 0.7-2500 mg/day, and once a day at regular time intervals according to the judgment of a doctor or pharmacist It may be administered in several divided doses.
  • the present invention provides a method for preventing or treating skin damage or inflammation, comprising administering the pharmaceutical composition to a subject.
  • the pharmaceutical composition of the present invention may be administered in a therapeutically effective amount or a pharmaceutically effective amount.
  • the term “pharmaceutically effective amount” refers to an amount sufficient to treat a disease with a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level includes the subject type and severity, age, sex, drug activity, sensitivity to drugs, administration time, administration route and excretion rate, duration of treatment, factors including concurrent drugs, and other factors well known in the medical field.
  • the method of administering the pharmaceutical composition is not particularly limited, and examples thereof include methods such as application to the skin, intradermal injection, and subcutaneous injection.
  • the "subject" of the present invention means a subject in need of a method for preventing, controlling or treating a disease, and more specifically, a human or non-human primate, mouse, rat, dog , means mammals such as cats, horses, and cattle. Occasionally, humans may be excluded.
  • the present invention provides a cosmetic composition for preventing or improving skin damage or inflammation comprising red algae microfibrillated cellulose prepared by the above method.
  • the cosmetic composition for preventing or improving skin damage or inflammation of the present invention contains the above-described red algae fibrillar cellulose
  • the content overlapping with the red algae fibrillar cellulose of the present invention is overlapped with the description of the present specification In order to avoid excessive complexity, the description is omitted.
  • the cosmetic composition of the present invention may further include one or more cosmetically acceptable carriers to be formulated in general skin cosmetics, and common ingredients include, for example, oil, water, surfactant, humectant, lower alcohol, thickener, A chelating agent, a colorant, a preservative, a fragrance, etc. may be appropriately mixed, but the present invention is not limited thereto.
  • Products to which the cosmetic composition of the present invention can be added include, for example, cosmetics such as astringent lotion, softening lotion, nutritional lotion, various creams, essences, packs, foundations, and cleansing, face wash, soap, treatment, and serum. etc.
  • compositions of the present invention include skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nourishing lotion, massage cream, nourishing cream, moisture cream, hand cream, essence, nourishing essence, pack, It includes formulations such as soap, shampoo, cleansing foam, cleansing lotion, cleansing cream, body lotion, body cleanser, emulsion, lipstick, makeup base, foundation, press powder, loose powder, and eye shadow.
  • the active substance of the present invention may be added in an amount of 0.1 to 50% by weight, preferably 1 to 10% by weight, to the cosmetic composition usually contained therein.
  • red algae fibrillar cellulose of the present invention is used as an external preparation for skin, additionally, a fatty substance, an organic solvent, a solubilizer, a thickening agent and a gelling agent, an emollient, an antioxidant, a suspending agent, a stabilizer, a foaming agent, a fragrance, Surfactants, water, ionic or nonionic emulsifiers, fillers, sequestering and chelating agents, preservatives, vitamins, blocking agents, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipid vesicles or external preparations for skin It may contain adjuvants commonly used in the field of dermatology, such as any other ingredients commonly used in skin care. In addition, the ingredients may be introduced in an amount generally used in the field of dermatology.
  • the present invention provides a method for improving skin damage or alleviating inflammation comprising the step of topically applying the cosmetic composition to an individual in an effective amount.
  • the dosage of the cosmetic composition may be appropriately adjusted in consideration of the patient's health condition and the degree of skin damage.
  • it may be applied to the skin (eg, face, hand, arm, leg, foot, or whole body) at a dose of about 0.0001 to about 5 mg/cm 2 at a time for normal adults.
  • the "subject" of the present invention means a subject in need of a method for preventing, controlling or treating a disease, and more specifically, a human or non-human primate, mouse, rat, dog , means mammals such as cats, horses, and cattle. Occasionally, humans may be excluded.
  • the present invention provides a health food and health functional food composition for preventing or improving skin damage or inflammation comprising red algae microfibrillated cellulose prepared by the above method.
  • the health food and health functional food composition for preventing or improving skin damage or inflammation of the present invention contains the above-described red algae fibrillar cellulose, the content overlapping with the red algae fibrillar cellulose of the present invention is duplicated. In order to avoid excessive complexity of the present specification by description, the description is omitted.
  • the food composition of the present invention may be formulated in various forms, such as tablets, pills, granules, capsules, liquid preparations, and beverages, and added to food.
  • food There are no special restrictions on the type of food.
  • foods to which the red algae microfibrous cellulose of the present invention can be added include drinks, meat, sausage, bread, biscuits, rice cakes, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products including ice cream.
  • There are products, various soups, beverages, alcoholic beverages and vitamin complexes, dairy products and processed dairy products and includes both health food and health functional food in the ordinary sense.
  • the health food and health functional food composition containing red algae microfibrous cellulose according to the present invention may be added to food as it is or used together with other food or food ingredients, and may be appropriately used according to a conventional method.
  • the mixing amount of red algae fibrillar cellulose may be appropriately determined depending on the purpose of its use (for prevention or improvement).
  • the amount of the composition in health food and health functional food may be added in an amount of 0.1 to 90 parts by weight based on the total weight of the food.
  • the above amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount above the above range.
  • the health food and health functional food composition of the present invention is not particularly limited in other ingredients except for containing the red algae fibrillar cellulose of the present invention as an essential ingredient in the indicated ratio. It can contain as an ingredient.
  • natural carbohydrates include monosaccharides such as glucose, fructose and the like; disaccharides such as maltose, sucrose and the like; and polysaccharides such as conventional sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol.
  • natural flavoring agents such as, taumatine, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used.
  • the proportion of the natural carbohydrate is generally about 1 to 20 g, preferably about 5 to 12 g, per 100 of the nutraceutical composition of the present invention.
  • the health food and health functional food composition containing red algae fibrillar cellulose of the present invention are various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic flavoring agents and natural flavoring agents, coloring agents and thickeners (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like.
  • the health food and health functional food composition of the present invention may contain fruit for the production of natural fruit juice, fruit juice beverage, and vegetable beverage.
  • these components may be used independently or in combination. Although the proportion of these additives is not so important, it is generally selected in the range of 0.1 to about 20 parts by weight per 100 parts by weight of the health food and health functional food composition containing the red algae fibrillar cellulose of the present invention.
  • the present invention provides a method for confirming fibrillation of red algae cellulose, comprising the step of determining whether fibrillation of the fibers of the cellulose is fibrillated.
  • the step of determining whether or not the fibrillation is to measure the water retention value of cellulose, to check the degree of sedimentation (sedimentation) to determine whether an assembly is formed, or to bind cellulose and Ct CBD3 protein It may be to check
  • the water retention value is related to the binding force of the fibers and the cellulose surface area, and as more fibers are defibrillated, water retention increases. Therefore, it can be determined whether the fibrillation of the cellulose according to the water retention value (water retention value).
  • the degree of sedimentation can be confirmed through a sedimentation test, and the visible deposited layer exists as individual fibers or is entangled or incompletely separated fibers that interact with other fibers to form an assembly and visually fibers that can be observed. Therefore, it is possible to determine whether the cellulose is microfibrillated according to the settling height of the fibers.
  • the Ct CBD3 protein is known to be attached to the crystalline form of cellulose including CBM1, CBM2a, CBM3, CBM5, and CBM10, which are surface-binding-carbohydrate-binding modules. As the fibrillation progresses, the surface area of the cellulose increases and thus the Ct CBD3 protein binding rate increases. Therefore, it is possible to determine whether cellulose is microfibrillated according to the degree of binding of Ct CBD3 protein.
  • a sample was prepared by mixing 2 g of agar agar and 18 ml of distilled water so that the content of Gelidium amansii was 10% (w/v). Thereafter, the samples were pretreated at 120, 150 and 180° C. for 10 minutes using Microwave (MARS6 System, CEM Corporation, USA) Easy Prep TM (see Table 1).
  • the glucan and galactan contents of the sample of Example 1 were measured.
  • the glucan and galactan contents were measured as follows.
  • the method of Laboratory Analytical Procedure provided by the US Department of Energy's Renewable Energy Laboratory was referred to.
  • the dried assay sample (dry content: 25 mg) was reacted with 250 ⁇ l of 72% (w/w) sulfuric acid at 30° C. for 1 hour, then transferred to a serum bottle, diluted with 7 mL of distilled water to 4%, and reacted at 121° C. for an additional hour. .
  • the sample is centrifuged to separate the solid, and the supernatant is neutralized to pH 6-8 with calcium carbonate.
  • glucose and galactose contents were confirmed through HPLC analysis.
  • the glucan content means glucose, that is, the cellulose content
  • the galactan content means galactose, that is, the agar content.
  • the results are shown in Figure 1 and Table 2.
  • FIG. 1 is a graph showing the contents of glucan and galactan after microwave pretreatment of red algae agaric
  • FIG. 2 is a structure according to microwave pretreatment temperature of red algae agaric. This is a graph showing the change.
  • the control sample which was not pretreated, had the highest galactan content because agar was not removed, and the glucose content increased according to the pretreatment temperature and galactose ), it was confirmed that the content was decreased.
  • the peaks of 1315 cm -1 and 1371 cm -1 did not exist, and the higher the pretreatment temperature, the higher the cellulose content at the peak of 1110 cm -1 indicating the cellulose content. was shown.
  • the sample pretreated at 180 ° C. had a galactan content of 1.8%, and most of the agar was removed. Therefore, it can be seen that the sample is cellulose extracted from agar agar ( Gelidium amansii ). From the examples below, only samples pretreated at 180 °C were used.
  • Example 1 The sample pretreated at 180° C. of Example 1, that is, cellulose extracted from agar agar (Gelidium amansii ) was blended for 40, 80, 120 and 160 minutes, respectively, at 37000 RPM using a Vitamix TNC5200 blender (vitamix, japan). (blending) to prepare microfibrillated cellulose.
  • Example 3 In order to check whether the cellulose is microfibrillated, the water retention value of each of the samples of Example 3, that is, microfibrillated cellulose, was measured.
  • the water retention value is the ratio of the percentage of water contained in the sample after centrifugation with force and time to the dry weight of the sample.
  • WRV The water retention value
  • the sample was filled on top and placed in a centrifuge. After centrifugation at 4 °C with a relative centrifugal force (RCF) of 900 g for 30 min, the samples were weighed. After that, it was dried in a dry oven at 80 °C for 24 hours and dried at 103 °C until all moisture was removed. Water retention was calculated using Equation 1 below.
  • W wet is the weight of the sample after centrifugation
  • W dry the dry weight of the sample.
  • Figure 3 is a graph showing the water retention (water retention value) according to the physical treatment (blending) time of red algae cellulose.
  • a negative control (0 min)
  • the sample pretreated at 180° C. of Example 1 without blending treatment was used, and as a positive control, Borregard MFC was used.
  • the experimental group had a significantly higher water retention value than the control group that did not perform blending, which is a physical pretreatment step.
  • the sample blended for 80 minutes or more maintains high water retention.
  • Fibrillation was confirmed through the physical pretreatment step of cellulose extracted from agar agar, and this result means that microfibrillated cellulose was formed from agar agar by blending.
  • Example 3 In order to confirm whether the cellulose is microfibrillated, a sedimentation test of each of the samples of Example 3, that is, microfibrillated cellulose, was performed.
  • the degree of precipitation is a method that can confirm the dispersion stability of the MFC suspension.
  • agar agar cellulose samples were prepared at a concentration of 0.05% 0.1% 0.2% 0.4%, and then thoroughly mixed before the precipitation test. And it was left for 48 hours to allow the precipitate to settle. After the cellulose fibers were completely submerged, the height of the sediment was measured. The results are shown in FIG. 4 .
  • the visible precipitated layer refers to fibers that can be visually observed as cellulose fibers are microfibrillated and the separated fibers interact with other fibers to form an assembly (see FIG. 6 ).
  • x-axis Hs (height of sedimentation)/Ho (height before sedimentation)
  • y-axis means concentration.
  • the Hs/Ho value is significantly increased in the samples subjected to blending (40 minutes, 80 minutes, 120 minutes, and 160 minutes). Since there is a difference in the Hs/Ho values depending on the presence or absence of blending, it can be seen that the microfibrillation of the fibers is increased when the physical treatment is performed.
  • the sample blended for 160 minutes among the samples of Example 3 showed a sedimentation height close to that of the positive control group (Borregard MFC) at the same concentration.
  • Binding experiments were performed by adding 200 ⁇ g/mL of Ct CBD3 to the substrate for 1 mg of fibrillar cellulose.
  • the substrate and protein were reacted with a total of 500 ⁇ L of 50 mM potassium phosphate buffer (pH 7.0) at 4 °C for 30 minutes.
  • the supernatant was separated by centrifugation at 13,000 rpm and 4°C for 10 minutes. The amount of protein remaining in the supernatant without binding to the substrate through BCA was measured. The results are shown in FIG. 5 .
  • 5 is a graph showing the binding force between cellulose and Ct CBD3 protein according to the physical treatment (blending) time of red algae cellulose.
  • cyclooxygenase-2 (Cox-2) was measured to confirm the skin damage and inflammation inhibitory effect of the microfibrillated cellulose prepared in Example 3 above.
  • HaCaT cells were seeded in a 6 cm dish at a concentration of 3 ⁇ 10 5 cells/mL and cultured in an incubator at 37° C. and 5% CO 2 conditions. Thereafter, the concentration of the fibrillar cellulose of Example 3 was pre-treated with 50 and 100 ⁇ g/mL for 1 hour, followed by UVB (0.03 J/cm 2 ) treatment and cultured for 4 hours. Then, the dish was placed on ice, washed twice with cold PBS, and then lysed with a cell lysis buffer (lysis buffer, Cell Signaling Technologies).
  • lysis buffer lysis buffer, Cell Signaling Technologies
  • Lysis buffer was recovered with a cell scraper, transferred to a 1.5 mL tube, and then vortexed on ice once every 10 minutes for a total of 3 times. After centrifugation in a centrifuge at 4 °C and 12,000 rpm for 15 minutes to obtain a supernatant, the protein was quantified using a DC Protein Assay Kit reader (Bio-Rad Inc.).
  • PVDF polyvinylidene difluoride
  • the membrane was washed three times once every 5 minutes by changing TBST (tris-buffered saline Tween-20), and a secondary antibody (horseradish peroxidase (HRP) labeled with HRP dissolved in skim milk) )-conjugated secondary antibody, Thermo Scientific) at room temperature for 1 hour.
  • TBST tris-buffered saline Tween-20
  • HRP horseradish peroxidase
  • Thermo Scientific Thermo Scientific
  • EzWestLumi plus was treated to measure protein expression and phosphorylation. Protein bands were quantified and visualized using a chemiluminescence detection kit (ATTO, Tokyo, Japan) and GeneGnome XRQ NPC (Syngene, Cambridge, UK), respectively. The results are shown in FIG. 7 .
  • HaCaT Human Adult Low Calcium High Temperature skin cells were pretreated with the MFC of Example 3 at 0, 25, 50 and 100 ⁇ g/mL for 1 hour, respectively, stimulated with UVB irradiation, and harvested after 10 or 30 minutes.
  • Phosphorylation and expression levels of MAPKs JNK1/2, p38 and ERK1/2 were detected by Western blot using specific antibodies. Western blot was performed in the same manner as in the experimental method described in Example 5 above. The results are shown in FIG. 8 .
  • the MFC of Example 3 was shown to inhibit UVB-induced phosphorylation of JNK1/2 and p38 in HaCaT cells.
  • HaCaT Human Adult Low Calcium High Temperature skin cells were pretreated with the MFC of Example 3 at 0, 50 and 100 ⁇ g/mL for 1 hour, respectively, stimulated with UVB irradiation, and harvested after 10 or 30 minutes.
  • Total RNA was isolated from HaCaT cells using RNAiso Plus (TAKARA, China). The isolated total RNA was used for cDNA synthesis using ReverTra Ace® qPCR RT master mix (Toyobo, Japan). Then, RT-PCR was performed using SYBR® Green Realtime PCR Master Mix (Toyobo, Japan). The level of TNF- ⁇ mRNA was measured using CFX Real-Time PCR Detection Systems (Bio-Rad). Relative gene expression was corrected (normalized) with glyceraldehyde-3-phosphate dehydrogenase using the 2- ⁇ CT method to reduce inherent errors in the experiment. The results are shown in FIG. 9 .

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Birds (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne un procédé de préparation de cellulose microfibrillée (MFC) d'algue rouge, et une utilisation de celle-ci, et la MFC d'algue rouge préparée par le procédé de préparation de la présente invention présente un excellent effet inhibiteur sur l'activité cyclooxygénase 2 (Cox-2), un excellent effet inhibiteur sur la phosphorylation des MAPK et un excellent effet inhibiteur sur l'expression de TNF-α, et supprime ainsi les lésions cutanées et l'inflammation causées par les rayons ultraviolets.
PCT/KR2021/003752 2020-04-14 2021-03-26 Procédé de préparation de cellulose microfibrillée d'algue rouge, et son utilisation WO2021210804A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2020-0045030 2020-04-14
KR20200045030 2020-04-14
KR1020210037118A KR102587264B1 (ko) 2020-04-14 2021-03-23 홍조류 미소섬유상 셀룰로오스 제조방법 및 이의 용도
KR10-2021-0037118 2021-03-23

Publications (1)

Publication Number Publication Date
WO2021210804A1 true WO2021210804A1 (fr) 2021-10-21

Family

ID=78084818

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2021/003752 WO2021210804A1 (fr) 2020-04-14 2021-03-26 Procédé de préparation de cellulose microfibrillée d'algue rouge, et son utilisation

Country Status (1)

Country Link
WO (1) WO2021210804A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005508999A (ja) * 2001-11-14 2005-04-07 ラレナ アマノリ属紅藻の抽出物を含有する製品およびそれの細胞保護剤としての使用
US20160145805A1 (en) * 2013-06-20 2016-05-26 Basf Se Process for the production of a microfibrillated cellulose composition
JP2017132725A (ja) * 2016-01-29 2017-08-03 御木本製薬株式会社 美白剤、小じわ改善剤、抗炎症剤、抗アレルギー剤。

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005508999A (ja) * 2001-11-14 2005-04-07 ラレナ アマノリ属紅藻の抽出物を含有する製品およびそれの細胞保護剤としての使用
US20160145805A1 (en) * 2013-06-20 2016-05-26 Basf Se Process for the production of a microfibrillated cellulose composition
JP2017132725A (ja) * 2016-01-29 2017-08-03 御木本製薬株式会社 美白剤、小じわ改善剤、抗炎症剤、抗アレルギー剤。

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GAHROOEE TINA RAEISI; ABBASI MOUD AREF; DANESH MARZIYEH; HATZIKIRIAKOS SAVVAS G.: "Rheological characterization of CNC-CTAB network below and above critical micelle concentration (CMC)", CARBOHYDRATE POLYMERS, vol. 257, 12 January 2021 (2021-01-12), GB , XP086480650, ISSN: 0144-8617, DOI: 10.1016/j.carbpol.2020.117552 *
JANG, JEONG HWA.: "Potential Application of Cellulose Nanofiber as a Functional Cosmetic Material and Intelligent Packaging Material", THESIS, October 2020 (2020-10-01), pages 1 - 84, XP009531394 *
JUNG, YEONGHUN ET AL.: "Final Report of Development and Standardization of Nanocellulose Derived from Red Algae as a Functional Cosmetic Material.", FINAL REPORT, no. TRKO202000031225, 4 May 2020 (2020-05-04), Korea, pages 1 - 50, XP009531393 *
SUMAN SINGH, KIRTIRAJ K. GAIKWAD, SU-IL PARK, YOUN SUK LEE: "Microwave-assisted step reduced extraction of seaweed ( Gelidiella aceroso ) cellulose nanocrystals", INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, vol. 99, 1 June 2017 (2017-06-01), NL , pages 506 - 510, XP055458490, ISSN: 0141-8130, DOI: 10.1016/j.ijbiomac.2017.03.004 *
XIANG ZHOUYANG; GAO WENHUA; CHEN LIHENG; LAN WU; ZHU J. Y.; RUNGE TROY: "A comparison of cellulose nanofibrils produced fromCladophora glomerataalgae and bleached eucalyptus pulp", CELLULOSE, vol. 23, no. 1, 22 December 2015 (2015-12-22), Netherlands , pages 493 - 503, XP035904015, ISSN: 0969-0239, DOI: 10.1007/s10570-015-0840-7 *

Similar Documents

Publication Publication Date Title
WO2016047907A1 (fr) Composition contenant des cellules mortes de lactobacillus tyndalisé comme ingrédient actif pour hydrater la peau ou atténuer les rides
WO2020060060A1 (fr) Composition cosmétique comprenant un extrait de racine adventive de centella asiatica en tant que principe actif pour le blanchiment de la peau et la réduction des rides
KR20050114677A (ko) Ｉ형 콜라겐 및/또는 엘라스틴 생산 촉진용 조성물
WO2020218846A1 (fr) Composition de blanchiment de la peau comprenant un exosome de lait
KR102126470B1 (ko) 용안육 추출물을 포함하는 화장료 조성물
WO2022177215A1 (fr) Procédé pour favoriser l'activité antioxydante de feuilles de thé pourpre
WO2020013610A1 (fr) Composition pour la prévention, l'atténuation ou le traitement de maladies cutanées allergiques, contenant, en tant que principe actif, un extrait de fruits de gardénia desquels des pigments sont retirés
WO2019143055A1 (fr) Composition comprenant un extrait de haricots fermentés obtenu à partir d'une fermentation par une souche d'aspergillus fumigatus, pour l'amélioration de soins cutanés
WO2018164369A1 (fr) Composition pour améliorer les rides de la peau, contenant un extrait d'hibiscus syriacus traité par une enzyme en tant que principe actif
WO2020246766A1 (fr) Composition pour prévenir ou atténuer le vieillissement cutané, contenant un extrait de rhodiola sachalinensis fermenté à l'aide de bovista plumbea
KR102587264B1 (ko) 홍조류 미소섬유상 셀룰로오스 제조방법 및 이의 용도
WO2018111042A2 (fr) Composition cosmétique comprenant un extrait de plantes médicinales en tant qu'ingrédient actif
WO2018056676A1 (fr) Composition pharmaceutique comprenant un extrait de maïs pourpre pour la prévention ou le traitement d'une maladie de la peau
WO2014025148A1 (fr) Extrait de cistanche tubulosa et de fucoïdane, présentant des effets de prévention de perte des cheveux et de promotion de croissance des cheveux, et procédé pour sa préparation
WO2016056781A1 (fr) Composition pour prévenir la chute des cheveux ou stimuler la pousse des cheveux comprenant un extrait d'artemisia umbelliformis
WO2020256464A1 (fr) Utilisation d'une fraction d'extrait de tubercule d'apios americana ayant une activité anti-inflammatoire comme agent préventif ou thérapeutique de la gastrite alcoolique, et son procédé de production
WO2015034247A1 (fr) Composition contenant un composé de monoacétyldiacylglycérol comme principe actif pour prévenir ou traiter la dermatite atopique
WO2020242113A1 (fr) Composition pour la prévention, le soulagement ou le traitement du syndrome métabolique accompagné de l'obésité et/ou du diabète, contenant, en tant que principe actif, un complexe (complexe ib) d'extrait de groseille indienne et d'extrait d'orge jeune
WO2021210804A1 (fr) Procédé de préparation de cellulose microfibrillée d'algue rouge, et son utilisation
WO2016056780A1 (fr) Composition pour prévenir la chute des cheveux ou stimuler la pousse des cheveux comprenant un extrait de scutellaria alpina
WO2020045921A1 (fr) Composition pour améliorer la transparence de la peau et diminuer son aspect terne
WO2015167240A1 (fr) Composition contenant un extrait de scutellaria alpina
WO2021215677A1 (fr) Composition pour atténuer les dommages cutanés au moyen d'un nanomatériau de cellulose dérivé d'algues rouges, et son procédé de préparation
WO2018066916A1 (fr) Nouvelle algue scédesmus sp. et extrait de cette dernière
WO2019031655A1 (fr) Composition comprenant du thymol comme principe actif pour prévenir ou traiter les rides de la peau ou la dermatite atopique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21789375

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21789375

Country of ref document: EP

Kind code of ref document: A1